Insulin aspart (Fiasp) vs Insulin lispro (Lyumjev)

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Type 2 Diabetes

Shared mechanism: Insulin receptor · full Type 2 Diabetes pipeline

Insulin aspart (Fiasp)

Marketed by Novo Nordisk

Approved in Type 2 Diabetespeptide
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

Next expected readout: June 2028 · NCT07652528 (registry estimate)

No aligned efficacy figure on record for this race.

Insulin lispro (Lyumjev)

Marketed by Eli Lilly

Approved in Type 2 Diabetespeptide
Partial signal

NCT03214380 · Phase 3 · completed

The study randomized and double-blinded participants to LY900014 or insulin lispro, with 933 enrolled and approximately 336-337 participants in the main comparison arms. The primary HbA1c endpoint met the prespecified non-inferiority margin, but HbA1c is a laboratory surrogate rather than a hard clinical endpoint, supporting a moderate evidence grade.

Reported efficacy

Change From Baseline in Hemoglobin A1c (HbA1c) (Baseline, Week 26): Change From Baseline in Hemoglobin A1c (HbA1c) (Baseline, Week 26): LY900014 -0.56 Percentage of HbA1c (Standard Error 0.046) vs Insulin Lispro (Humalog) -0.63 Percentage of HbA1c (Standard Error 0.061) (met)

Result source: NCT03952143

Results for Type 2 Diabetes

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointInsulin aspart (Fiasp)Insulin lispro (Lyumjev)
HbA1c, change6.6% vs 6.6%vs NovoRapidwk 26 · n 345NCT01819129
2 other results
  • -0.1% vs -0.1% wk 16 · n 544 · Phase 3 · primary NCT03268005
  • 6.8% vs 7.7% wk 18 · n 116 · Phase 3 · primary NCT01850615
-0.4% vs -0.4%vs Insulin Lispro (Humalog)wk 26 · n 334NCT03214380
1 other result
  • -0.6% vs -0.6% wk 26 · n 388 · Phase 3 · primary NCT03952143
Body weight, change (kg)1.2 vs 1.1vs NovoRapidwk 16 · n 522NCT03268005—Not reported
HbA1c below 7%—Not reported—Not reported
Fasting plasma glucose, change0.6 vs 0.7vs NovoRapidwk 16 · n 533NCT03268005—Not reported
3-point MACE (% with event)—Not reported—Not reported

HbA1c, change

Insulin aspart (Fiasp)
6.6% vs 6.6%vs NovoRapidwk 26 · n 345NCT01819129
2 other results
  • -0.1% vs -0.1% wk 16 · n 544 · Phase 3 · primary NCT03268005
  • 6.8% vs 7.7% wk 18 · n 116 · Phase 3 · primary NCT01850615
Insulin lispro (Lyumjev)
-0.4% vs -0.4%vs Insulin Lispro (Humalog)wk 26 · n 334NCT03214380
1 other result
  • -0.6% vs -0.6% wk 26 · n 388 · Phase 3 · primary NCT03952143

Body weight, change (kg)

Insulin aspart (Fiasp)
1.2 vs 1.1vs NovoRapidwk 16 · n 522NCT03268005
Insulin lispro (Lyumjev)
—Not reported

HbA1c below 7%

Insulin aspart (Fiasp)
—Not reported
Insulin lispro (Lyumjev)
—Not reported

Fasting plasma glucose, change

Insulin aspart (Fiasp)
0.6 vs 0.7vs NovoRapidwk 16 · n 533NCT03268005
Insulin lispro (Lyumjev)
—Not reported

3-point MACE (% with event)

Insulin aspart (Fiasp)
—Not reported
Insulin lispro (Lyumjev)
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. Insulin aspart (Fiasp): 4 of 4 rows · Insulin lispro (Lyumjev): 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricInsulin aspart (Fiasp)Insulin lispro (Lyumjev)
Dropout rate
12.8%a
NCT01819129 · Phase 3
show 2 more results
7.8%
NCT01850615 · Phase 3 · combination
2.7%
NCT03268005 · Phase 3 · registry result, not featured evidence
—b
NCT03214380 · Phase 3 · combination · Type 2 Diabetes · phase 3
show 16 more results
—
NCT03952143 · Phase 3 · combination · Type 2 Diabetes · phase 3
17.6%
NCT04605991 · Phase 3 · combination · Type 2 Diabetes · phase 3
—LY900014 After Meal
NCT03341312 · Phase 1 · registry result, not featured evidence
—LY900014 Before Meal
NCT03341312 · Phase 1 · registry result, not featured evidence
—15 U
NCT03286751 · Phase 1 · registry result, not featured evidence
—30 U
NCT03286751 · Phase 1 · registry result, not featured evidence
—7 U
NCT03286751 · Phase 1 · registry result, not featured evidence
—15 U
NCT03305822 · Phase 1 · registry result, not featured evidence
—15 U
NCT03232983 · Phase 1 · registry result, not featured evidence
—15 U
NCT03232983 · Phase 1 · registry result, not featured evidence
—15 U
NCT03232983 · Phase 1 · registry result, not featured evidence
—15 U
NCT03232983 · Phase 1 · registry result, not featured evidence
—LY900014 - Test (Part B)
NCT02703337 · Phase 1 · registry result, not featured evidence
—LY900014 - Test +15 Min (Part A)
NCT02703337 · Phase 1 · registry result, not featured evidence · combination
—LY900014 - Test -15 Min (Part A)
NCT02703337 · Phase 1 · registry result, not featured evidence
—LY900014 - Test 0 Min (Part A)
NCT02703337 · Phase 1 · registry result, not featured evidence
Discontinued due to AEs
0.3%a
NCT01819129 · Phase 3
show 2 more results
1.7%
NCT01850615 · Phase 3 · combination
—
NCT03268005 · Phase 3 · registry result, not featured evidence
—b
NCT03214380 · Phase 3 · combination · Type 2 Diabetes · phase 3
show 16 more results
—
NCT03952143 · Phase 3 · combination · Type 2 Diabetes · phase 3
2.7%
NCT04605991 · Phase 3 · combination · Type 2 Diabetes · phase 3
—LY900014 After Meal
NCT03341312 · Phase 1 · registry result, not featured evidence
—LY900014 Before Meal
NCT03341312 · Phase 1 · registry result, not featured evidence
—15 U
NCT03286751 · Phase 1 · registry result, not featured evidence
—30 U
NCT03286751 · Phase 1 · registry result, not featured evidence
—7 U
NCT03286751 · Phase 1 · registry result, not featured evidence
—15 U
NCT03305822 · Phase 1 · registry result, not featured evidence
—15 U
NCT03232983 · Phase 1 · registry result, not featured evidence
—15 U
NCT03232983 · Phase 1 · registry result, not featured evidence
—15 U
NCT03232983 · Phase 1 · registry result, not featured evidence
—15 U
NCT03232983 · Phase 1 · registry result, not featured evidence
—LY900014 - Test (Part B)
NCT02703337 · Phase 1 · registry result, not featured evidence
—LY900014 - Test +15 Min (Part A)
NCT02703337 · Phase 1 · registry result, not featured evidence · combination
—LY900014 - Test -15 Min (Part A)
NCT02703337 · Phase 1 · registry result, not featured evidence
—LY900014 - Test 0 Min (Part A)
NCT02703337 · Phase 1 · registry result, not featured evidence
Serious AEs
4.4%a
NCT01819129 · Phase 3
show 2 more results
5.2%
NCT01850615 · Phase 3 · combination
7%
NCT03268005 · Phase 3 · registry result, not featured evidence
7.7%b
NCT03214380 · Phase 3 · combination · Type 2 Diabetes · phase 3
show 16 more results
8.4%
NCT03952143 · Phase 3 · combination · Type 2 Diabetes · phase 3
1.7%
NCT04605991 · Phase 3 · combination · Type 2 Diabetes · phase 3
0%LY900014 After Meal
NCT03341312 · Phase 1 · registry result, not featured evidence
0%LY900014 Before Meal
NCT03341312 · Phase 1 · registry result, not featured evidence
0%15 U
NCT03286751 · Phase 1 · registry result, not featured evidence
0%30 U
NCT03286751 · Phase 1 · registry result, not featured evidence
0%7 U
NCT03286751 · Phase 1 · registry result, not featured evidence
0%15 U
NCT03305822 · Phase 1 · registry result, not featured evidence
0%15 U
NCT03232983 · Phase 1 · registry result, not featured evidence
0%15 U
NCT03232983 · Phase 1 · registry result, not featured evidence
0%15 U
NCT03232983 · Phase 1 · registry result, not featured evidence
0%15 U
NCT03232983 · Phase 1 · registry result, not featured evidence
0%LY900014 - Test (Part B)
NCT02703337 · Phase 1 · registry result, not featured evidence
0%LY900014 - Test +15 Min (Part A)
NCT02703337 · Phase 1 · registry result, not featured evidence · combination
0%LY900014 - Test -15 Min (Part A)
NCT02703337 · Phase 1 · registry result, not featured evidence
0%LY900014 - Test 0 Min (Part A)
NCT02703337 · Phase 1 · registry result, not featured evidence
Most frequent reported AEs
a
urinary tract infection 5.9%
nasopharyngitis 5%
upper respiratory tract infection 4.7%
NCT01819129 · Phase 3
show 2 more results
diarrhoea 1.7%
NCT01850615 · Phase 3 · combination
nasopharyngitis 5.9%
NCT03268005 · Phase 3 · registry result, not featured evidence
b
nasopharyngitis 14%
upper respiratory tract infection 8%
diarrhoea 3.3%
NCT03214380 · Phase 3 · combination · Type 2 Diabetes · phase 3
show 15 more results
upper respiratory tract infection 5.3%
NCT03952143 · Phase 3 · combination · Type 2 Diabetes · phase 3
injection site reaction 5.6%
NCT03341312 · Phase 1 · registry result, not featured evidence
injection site reaction 2.9%
NCT03341312 · Phase 1 · registry result, not featured evidence
15 U
headache 10%
nausea 5%
injection site reaction 2.5%
NCT03286751 · Phase 1 · registry result, not featured evidence
30 U
headache 14.6%
injection site reaction 14.6%
nausea 7.3%
NCT03286751 · Phase 1 · registry result, not featured evidence
7 U
headache 15%
injection site reaction 2.5%
nausea 2.5%
NCT03286751 · Phase 1 · registry result, not featured evidence
15 U
headache 5.3%
vessel puncture site thrombosis 5.3%
NCT03305822 · Phase 1 · registry result, not featured evidence
15 U
infusion site pain 12%
catheter site bruise 8%
vessel puncture site bruise 8%
NCT03232983 · Phase 1 · registry result, not featured evidence
15 U
injection site pain 11.5%
application site erythema 7.7%
catheter site bruise 7.7%
NCT03232983 · Phase 1 · registry result, not featured evidence
15 U
catheter site pain 10.7%
catheter site swelling 7.1%
application site erythema 3.6%
NCT03232983 · Phase 1 · registry result, not featured evidence
15 U
catheter site bruise 7.7%
infusion site erythema 7.7%
infusion site swelling 7.7%
NCT03232983 · Phase 1 · registry result, not featured evidence
headache 6.7%
back pain 0%
thrombophlebitis 0%
NCT02703337 · Phase 1 · registry result, not featured evidence
back pain 0%
headache 0%
thrombophlebitis 0%
NCT02703337 · Phase 1 · registry result, not featured evidence · combination
thrombophlebitis 6.9%
back pain 0%
headache 0%
NCT02703337 · Phase 1 · registry result, not featured evidence
thrombophlebitis 10.3%
back pain 0%
headache 0%
NCT02703337 · Phase 1 · registry result, not featured evidence

Notes

  1. aPopulation comparability has not been reviewed for these studies.
  2. bPopulation comparability has not been reviewed for 14 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Insulin aspart (Fiasp)

PPG Excursion 4.55 vs 4.9 NovoRapid mmol/L @ 26wk
absolute change · mmol/L
NCT01819129 · Phase 3
show 1 more result
-0.43 vs 0.08 NovoRapid mmol/L @ 16wk
NCT03268005 · Phase 3 · registry result, not featured evidence
Fasting Plasma Glucose 0.56 vs 0.68 NovoRapid mmol/L @ 16wk
absolute change · mmol/L
NCT03268005 · Phase 3 · registry result, not featured evidence
HbA1c Less Than 7% 49.6% (n=546) vs 51.7% (n=545) NovoRapid @ 16wk
event count · % of participants
NCT03268005 · Phase 3 · registry result, not featured evidence · converted to % from 271 Participants as posted
HbA1c Less Than 7 Without Severe Hypoglycemia 48.5% (n=546) vs 51% (n=545) NovoRapid @ 16wk
event count · % of participants
NCT03268005 · Phase 3 · registry result, not featured evidence · converted to % from 265 Participants as posted
SMBG Daily Average -0.56 vs -0.5 NovoRapid mmol/L @ 16wk
absolute change · mmol/L
NCT03268005 · Phase 3 · registry result, not featured evidence
SMPG-mean Post Prandial Increment -0.48 vs -0.23 NovoRapid mmol/L @ 16wk
absolute change · mmol/L
All meals
NCT03268005 · Phase 3 · registry result, not featured evidence
Postprandial Glucose Leq 7.8 34.1% (n=546) vs 35.2% (n=545) NovoRapid @ 16wk
event count · % of participants
NCT03268005 · Phase 3 · registry result, not featured evidence · converted to % from 186 Participants as posted
Postprandial Glucose Leq 7.8 mmol/L Without Severe Hypoglycemia 33.3% (n=546) vs 34.9% (n=545) NovoRapid @ 16wk
event count · % of participants
NCT03268005 · Phase 3 · registry result, not featured evidence · converted to % from 182 Participants as posted
Weight 1.19 vs 1.12 NovoRapid kg @ 16wk
absolute change · kg
NCT03268005 · Phase 3 · registry result, not featured evidence
BMI 0.43 vs 0.4 NovoRapid kg @ 16wk
absolute change · kg
NCT03268005 · Phase 3 · registry result, not featured evidence

Insulin lispro (Lyumjev)

HbA1c 7.0 or Less 58.2% (n=316) vs 52.5% (n=320) Insulin Lispro (Humalog) @ 26wk
event count · % of participants
NCT03214380 · Phase 3 · combination · Type 2 Diabetes · phase 3 · converted to % from 184 Participants as posted
PPG 1H Excursion mg/dL 86.2 vs 100.8 Insulin Lispro (Humalog) mg @ 26wk
absolute value · mg
NCT03952143 · Phase 3 · combination · Type 2 Diabetes · phase 3
PPG 2 h Excursion mg/dL 6.18 vs 7.39 Insulin Lispro (Humalog) mmol/L @ 26wk
absolute value · mmol/L
NCT03952143 · Phase 3 · combination · Type 2 Diabetes · phase 3 · converted to mmol/L from 111.4 mg/dL as posted
HbA1c Less Than 7% 46.65% (n=358) vs 44.5% (n=191) Insulin Lispro (Humalog) @ 26wk
responder rate · % of participants
HbA1c < 7%
NCT03952143 · Phase 3 · combination · Type 2 Diabetes · phase 3
HbA1c 6 5 or Less 27.93% (n=358) vs 27.23% (n=191) Insulin Lispro (Humalog) @ 26wk
responder rate · % of participants
HbA1c ≤ 6.5%
NCT03952143 · Phase 3 · combination · Type 2 Diabetes · phase 3
Time in Range Daytime 3.8 % of time @ 12wk
absolute change · % of time
No placebo or comparator arm
NCT04605991 · Phase 3 · combination · Type 2 Diabetes · phase 3
HbA1c -0.44% (n=167) @ 12wk
absolute change · percentage points
No placebo or comparator arm
NCT04605991 · Phase 3 · combination · Type 2 Diabetes · phase 3
Time in Range 24 h 3.3 % of time @ 12wk
absolute change · % of time
No placebo or comparator arm
NCT04605991 · Phase 3 · combination · Type 2 Diabetes · phase 3
Time Below 54 0 % of time @ 12wk
absolute change · % of time
No placebo or comparator arm
24-hour Period
NCT04605991 · Phase 3 · combination · Type 2 Diabetes · phase 3
Time Above 180 -3.4 % of time @ 12wk
absolute change · % of time
No placebo or comparator arm
24-Hour Period
NCT04605991 · Phase 3 · combination · Type 2 Diabetes · phase 3
Time Above 2.50 -1.07 % of time @ 12wk
absolute change · % of time
No placebo or comparator arm
24-Hour Period
NCT04605991 · Phase 3 · combination · Type 2 Diabetes · phase 3
Postprandial iAUC 0 1H -2.46 mg @ 12wk
absolute change · mg
No placebo or comparator arm
Overall - across meals
NCT04605991 · Phase 3 · combination · Type 2 Diabetes · phase 3

+ 7 further endpoints in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Insulin aspart (Fiasp)'s landscape · Insulin lispro (Lyumjev)'s landscape